Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin-Reference-Cited by-同舟云学术

Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin

Published:2020-01-27 Issue:8 Volume:42 Page:1728-1737
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Swiecicki Paul L.¹²^ORCID,Li Pin³,Bellile Emily³,Stucken Chaz⁴,Malloy Kelly⁴,Shuman Andrew⁴⁵,Spector Matthew E.⁴^ORCID,Chinn Steven⁴,Casper Keith⁴,McLean Scott⁴,Moyer Jeffery⁴⁵,Chepeha Douglas⁴,Wolf Gregory T⁴,Prince Mark⁴⁵,Bradford Carol⁴^ORCID,Nyati Mukesh⁶,Eisbruch Avraham⁶,Worden Francis P⁶,Jolly Shruti⁶,Mierzwa Michelle⁶⁷

Affiliation:

1. Department of Internal MedicineUniversity of Michigan Ann Arbor Michigan

2. Department of Internal MedicineAnn Arbor Veterans Affairs Medical Center Ann Arbor Michigan

3. Department of BiostatisticsUniversity of Michigan School of Public Health Ann Arbor Michigan

4. Department of Otolaryngology‐Head and Neck SurgeryUniversity of Michigan Ann Arbor Michigan

5. Department of OtolaryngologyAnn Arbor Veterans Affairs Medical Center Ann Arbor Michigan

6. Department of Radiation OncologyUniversity of Michigan Ann Arbor Michigan

7. Department of Radiation OncologyAnn Arbor Veterans Affairs Medical Center Ann Arbor Michigan

Funder

National Institutes of Health

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26085

Reference27 articles.

1. Global cancer statistics, 2012

2. Trends in head and neck cancer incidence in relation to smoking prevalence

3. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

4. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data

5. Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review;Journal of Cancer Research and Clinical Oncology;2024-08-02

2. Rethinking treatment paradigms: Neoadjuvant therapy and de-escalation strategies in HPV-positive head and neck cancer;Critical Reviews in Oncology/Hematology;2024-04

3. Prediction of the Efficacy of Radiotherapy in Head-and-neck Tumors Patients by Dosiomics and Radiomics;Biomedical and Biotechnology Research Journal;2024-01

4. De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: evolving paradigms and future strategies;Frontiers in Oncology;2023-07-27

5. Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation;Journal of Clinical Oncology;2023-05-01